Processing

Please wait...

Settings

Settings

Goto Application

1. WO2019057765 - CRYSTALLINE SALTS OF A DEXTROAMPHETAMINE PRODRUG

Publication Number WO/2019/057765
Publication Date 28.03.2019
International Application No. PCT/EP2018/075338
International Filing Date 19.09.2018
IPC
A61K 31/165 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
C07C 237/06 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
237Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
02having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
04the carbon skeleton being acyclic and saturated
06having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
A61K 47/54 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
A61P 3/04 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
04Anorexiants; Antiobesity agents
A61P 25/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
CPC
A61K 47/541
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
541Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
C07B 2200/07
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
2200Indexing scheme relating to specific properties of organic compounds
07Optical isomers
C07C 237/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
237Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
02having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
04the carbon skeleton being acyclic and saturated
06having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Applicants
  • SANDOZ AG [CH]/[CH]
Inventors
  • LENGAUER, Hannes
  • PICHLER, Arthur
  • MARGREITER, Renate
Agents
  • KLUSCHANZOFF, Harald
  • ENGLMEIER, Ludwig
Priority Data
17192115.820.09.2017EP
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CRYSTALLINE SALTS OF A DEXTROAMPHETAMINE PRODRUG
(FR) SELS CRISTALLINS D'UN PROMÉDICAMENT DE DEXTROAMPHÉTAMINE
Abstract
(EN)
The present invention relates to crystalline salts of L-lysine-d-amphetamine and to a pharmaceutical composition comprising one or more of said crystalline salts, preferably in a predetermined and/or effective amount, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of Attention Deficit and Hyperactivity Disorder (ADHD) and Binge Eating Disorder (BED) symptoms.
(FR)
La présente invention concerne des sels cristallins de L-lysine-d-amphétamine et une composition pharmaceutique comprenant un ou plusieurs desdits sels cristallins, de préférence dans une quantité prédéterminée et/ou efficace, et au moins un excipient pharmaceutiquement acceptable. La composition pharmaceutique de la présente invention peut être utilisée en tant que médicament, en particulier pour le traitement du trouble du déficit de l'attention avec hyperactivité (TDAH) et des symptômes de trouble d'hyperphagie boulimique (HB).
Also published as
Latest bibliographic data on file with the International Bureau